Why is BRKR up?
Up 57% in a year while the S&P 500 rose 11%.
“With BSI organic bookings and backlog both up mid-single digits % year-to-date, we expect revenue growth acceleration”
BRKR's Quality Score rose 3 points on Fri, Nov 6, to 8. Its price is above its average prices of the last 8, 21, 50, and 200 days, which line up in that order (3 chart checks started).
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 57% in a year while the S&P 500 rose 11%.
“With BSI organic bookings and backlog both up mid-single digits % year-to-date, we expect revenue growth acceleration”
| The chart | Stronger than 90% of stocks |
| Latest filing | 8-K, Nov 4 |
After its last 4 reports it closed -2.3% on average, higher 2 of 4 times.
Averagefor quality, not price, 5 of 14 chart checks firingWhat the Quality Score means
Well above its recent run. BRKR scores 8 today, against a median of 4 over its last 20 recorded sessions.
BRKR is #8 of 15 by Quality Score among Laboratory Analytical Instruments.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 8 |
Net income over four quarters: BRKR -$71.2M, A $1.44B, MTD $906M, BIO $222M.
Expected to report Thu Feb 11, before the open (in 96 days). Expected.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $874.0M, 2% more than a year ago.
“In the third quarter, we achieved very significant margin expansion and non-GAAP EPS growth, driven by our focus on cost discipline and execution.”
BRKR's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| Foreign currency effect on revenue | Foreign currency neutral |
“With BSI organic bookings and backlog both up mid-single digits % year-to-date, we expect revenue growth acceleration, continued margin expansion and double-digit EPS growth in FY27.”
From its results filing (SEC filing · Nov 4)
Sales grew 12% a year over 5 years, fiscal 2020 to 2025.
Pays $0.20 a share a year.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Nov 4, 2026 | +15.7% | +12.9% | open |
| Aug 4, 2026 | -15.9% | -21.8% | -12.4% |
| May 6, 2026 | +10.2% | +11.3% | +17.7% |
Sales grew in six of the last seven years, to $3.4B in 2025. It lost money in 2025 after a profit in 2024.
2 insiders sold $736K across 6 filings in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: BRKR is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies (BEST) . The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
“Our existing products and solutions and any products and solutions that we develop in the future may compete in multiple, highly competitive markets.”
BRKR scores 8 today, which Breakaway calls Average. It is #8 of 15 in Laboratory Analytical Instruments by Quality Score, with 5 of 14 chart checks firing. Up 57% in a year while the S&P 500 rose 11%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
BRKR scores 8 today, which Breakaway calls Average (6 to 10). That is #8 of 15 in Laboratory Analytical Instruments by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind BRKR's 8.
2 insiders sold $736K across 6 filings in the last 6 months. No open-market buys on record. The newest is Mark Munch, Exec Vp&pres Bruker Nano Inc., who sold $106K on Sep 15. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.